-

NovaBay Pharmaceuticals to Hold Conference Call and Webcast With Slide Presentation Today to Discuss Acquisition of DERMAdoctor

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that management will discuss its acquisition of DERMAdoctor on an investment community conference call and webcast with accompanying slide presentation today, Wednesday, September 29, 2021 beginning at 4:30 p.m. Eastern time.

Date/Time:

Wednesday, September 29, 4:30 p.m. ET / 1:30 p.m. PT

 

Pre-Registration:

Participants can pre-register for the conference call here:

 

Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

 

Dial In:

Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:

866-777-2509 from within the U.S.

412-317-5413 from outside the U.S.

The live webcast of the conference call with accompanying slide presentation also will be available at http://novabay.com/investors/events. The slide deck will also be posted here for those joining by phone. A replay of the call will be available beginning two hours after its completion through October 14, 2021 by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 10159955.

The webcast and accompany slide presentation will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals:

NovaBay Pharmaceuticals, Inc. is a pharmaceutical company focusing on high-quality, differentiated, anti-infective consumer products: Avenova®, the premier antimicrobial lid and lash spray, CelleRx® Clinical Reset™, a breakthrough product in the beauty category, and NeutroPhase® Skin and Wound Cleanser for wound healing.

About DERMAdoctor:

DERMAdoctor delivers on the promise that clinical skin therapy can be fun and easy, while still delivering significant, measurable results. According to its founder, Dr. Audrey Kunin, “We are a clinical skincare brand from a female dermatologist's point of view. Designed to be elegant, hypoallergenic, multitasking, problem-solving and highly effective.” Additional information is available at www.dermadoctor.com.

Contacts

Socialize and Stay informed on NovaBay’s progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
Avenova.com

CelleRx Clinical Reset Purchasing Information
For NovaBay CelleRx Clinical Reset purchasing information
Please call 877-CELLERX
www.CelleRx.com

NovaBay Contact
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com

Investor Contact
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

NovaBay Pharmaceuticals, Inc.

NYSEAM:NBY

Release Versions

Contacts

Socialize and Stay informed on NovaBay’s progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
Avenova.com

CelleRx Clinical Reset Purchasing Information
For NovaBay CelleRx Clinical Reset purchasing information
Please call 877-CELLERX
www.CelleRx.com

NovaBay Contact
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com

Investor Contact
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

More News From NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel. This prescription product is the only optic allograft manufactured using BioStem Technologies, Inc.’s (OTC: BSEM) proprietary process and is intended for use as a protective covering during the repair of ocular surfaces. The product launch follows a prev...

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces. Amniotic Tissue Allograft provides a protective environment or covering for repair of the cornea and conjunctiva, helping...

NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2023 and provides a business update. “Net product revenue reached $4.6 million for the quarter, up 26% from the prior year as we benefited from a particularly strong quarter in our wound care segment,” said Justin Hall, NovaBay CEO. “We continue to control expenses by optimizing digital marketing programs, which led to a 16% year-over-yea...
Back to Newsroom